Several biotech companies are working on developing longer-lasting therapies for weight loss using RNA interference, a Nobel Prize-winning science that degrades biological blueprints used by RNA to make proteins. By targeting specific genes involved in weight regulation, these companies aim to create medications that could be administered much less frequently than current options. This shift away from weekly drugs targeting hormones could lead to treatments that only need to be given twice a year or even less. This new approach has the potential to revolutionize obesity treatment and provide more effective and convenient options for patients.
Source link
For longer-lasting obesity drugs, biotechs turn to gene silencing
